FDA Warns New Jersey Compounder for Sterility, Repackaging Violations

Drug Industry Daily
A A
The FDA issued a warning letter to New Jersey drug compounder Ideal Specialty Apothecary citing “serious deficiencies” in its sterile drug production and for repackaging a cancer drug without a license.

To View This Article:

Login

Subscribe To Drug Industry Daily